Xencor Inc. Stock
Price
Target price
€9.95
€9.95
0.000%
-
0.000%
€22.44
13.03.26 / Stuttgart Stock Exchange
WKN: A1W96L / Symbol: XNCR / Name: Xencor / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Xencor Inc. Stock
There is no change in the price for Xencor Inc. today.
We see a rather positive sentiment for Xencor Inc. with 15 Buy predictions and 2 Sell predictions.
Based on the current price of 9.95 € the target price of 22 € shows a potential of 121.11% for Xencor Inc. which would more than double the current price.
Pros and Cons of Xencor Inc. in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xencor Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xencor Inc. | 0.000% | 4.737% | 4.188% | -14.957% | -21.654% | -61.731% | -74.223% |
| United Therapeutics | 1.490% | 13.960% | 17.057% | 66.631% | 9.853% | 124.164% | 250.299% |
| Iovance Biotherapeutics Inc. | -1.520% | -21.720% | 59.719% | 6.635% | 46.016% | -42.790% | -88.067% |
| Ligand Pharmaceuticals | -6.250% | 1.667% | 16.561% | 69.444% | 10.241% | 191.773% | 33.091% |
Comments
Xencor (XNCR) had its price target raised by Barclays PLC from $26.00 to $27.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
Xencor (NASDAQ:XNCR) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
Xencor (NASDAQ:XNCR) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $26.00 price target on the stock.
Show more
Ratings data for XNCR provided by MarketBeat